As healthcare professionals, we are witnessing an alarming increase in obesity rates worldwide. This rise is accompanied by a surge in associated comorbidities like type 2 diabetes, cardiovascular diseases, and certain types of cancer. Hence, it is crucial to explore effective strategies for managing obesity.
Behavioral interventions form the cornerstone of obesity management. They involve dietary modifications, physical activity enhancement, and behavioral changes. These interventions can be delivered individually or in groups, face-to-face or remotely. The key is to customize the approach based on patient's needs and preferences.
Pharmacotherapy can be considered in patients with a BMI ≥30 or ≥27 with comorbidities, who have not responded to behavioral interventions. The choice of drug should be guided by the patient's comorbid conditions, potential side effects, and cost. Regular follow-up is essential to monitor efficacy and adverse effects.
Endoscopic and surgical interventions are reserved for patients with severe obesity (BMI ≥40 or ≥35 with comorbidities) who have not responded to non-surgical strategies. While these methods have shown significant weight loss and improvement in comorbid conditions, they are associated with potential complications and require lifelong medical follow-up.
Managing obesity requires an interdisciplinary approach involving dietitians, exercise physiologists, behavioral therapists, pharmacists, and surgeons. This team-based approach ensures comprehensive care, addressing all aspects of obesity.
Obesity management is a complex, multifaceted process requiring a personalized, patient-centered approach. It involves behavioral interventions, pharmacotherapy, endoscopic or surgical interventions, and an interdisciplinary team approach. As healthcare professionals, we need to stay updated with the latest evidence-based strategies to provide optimal care to our patients with obesity.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation